BEIJING, CHINA - SEPTEMBER 24: A worker checks syringes of the potential vaccine CoronaVac on the production line at Sinovac Biotech where the company is producing their potential COVID-19 vaccine CoronaVac during a media tour on September 24, 2020 in Beijing, China. Sinovacs inactivated vaccine candidate, called CoronaVac, is among a number of companies in the global race to control the coronavirus pandemic. The company is running Phase 3 human trials in four countries and ramping up production to 300 million doses per year at a new manufacturing facility south of Beijing. A lack of domestic coronavirus cases in China has meant that companies developing vaccines have shifted their focus overseas to conduct trials to gather the volume of data necessary to win regulatory approvals. When Chinas government launched an emergency use program in July to vaccinate groups of essential workers, Sinovacs chief executive says the company supplied tens of thousands of doses, even as trials are still underway. About 90% of Sinovacs employees have chosen to receive injections of CoronaVac, which is one of eight Chinese vaccine candidates in human trials. The company is also seeking approval to begin clinical trials with teenagers and children as young as age 3.(Photo by Kevin Frayer/Getty Images)
Bota

Kina aprovon vaksinën e saj “Sinovac” për përdorim te fëmijët

Nga Admin7
337

Kina ka aprovuar vaksinën e saj “Sinovac” kundër COVID-19 për përdorim tek fëmijët mes tre deri 17 vjeç, bëri të ditur kryetari i kompanisë, Yin Weidong.

Që nga nisja e vaksinimit masiv kundër COVID-19, Kina deri tani ka administruar 723.5 milionë doza të vaksinave, shkruan Reuters, transmeton Klankosova.tv.

Kur vaksina e Sinovac do t’ju ofrohet grupeve më të reja varet nga autoritetet shëndetësore që formulojnë strategjitë e vaksinimit në Kinës, tha Weidong.

Weidong tha se të miturit kanë përparësi më të ulët për vaksinimin kundër koronavirusit krahasuar me të moshuarit, të cilët përballen me rrezik më të lartë të simptomave të rënda pas infektimit.

Comments